Meeting
2020 Genitourinary Cancers Symposium
Baseline lymphocyte to monocyte ratio (LMR) and systemic inflammation index (SII) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.
Authors
Sara Elena Rebuzzi
Medical Oncology Unit 1, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova, Italy
Sara Elena Rebuzzi , Sebastiano Buti , Andrea Sbrana , Giuseppe Procopio , Ugo De Giorgi , Maria Giuseppa Vitale , Francesco Massari , Daniele Santini , Alessia Cavo , Giuseppe Luigi Banna , Mariella Soraru' , Alessio Cortellini , Marco Messina , Valentino Martelli , Veronica Mollica , Marco Stellato , Helga Lipari , Fabio Catalano , Alessio Signori , Giuseppe Fornarini
Organizations
Medical Oncology Unit 1, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Policlinico San Martino, Genova, Italy, Medical Oncology Unit, University Hospital of Parma, Parma, Italy, Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, Oncology Unit, Azienda Policlinico-Universitaria di Modena, Modena, Italy, Division of Oncology, S. Orsola-Malpighi Hospital, Bologna, Italy, Department of Medical Oncology, Campus Bio-Medico-University of Rome, Rome, Italy, Oncology Unit, Villa Scassi Hospital, Genova, Italy, Cannizzaro Hospital, Catania, Italy, Oncology Unit, Camposampietro Hospital, Camposampiero (Padua), Italy, Medical Oncology, St Salvatore Hospital, Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L'aquila, Italy, Unit of Medical Oncology, Istituto Fondazione G. Giglio, Palermo, Italy, Azienda Ospedaliera di Bologna, Bologna, Italy, Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy, Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy, Department of Health Sciences, Section of Biostatistics, University of Genoa, Genova, Italy
Research Funding
No funding received
None.
Background: Biomarkers to select mRCC patients most likely to benefit to immune-checkpoint inhibitors are still needed. The ongoing retrospective multicentre Meet-URO 15 (I-BIO-REC) study evaluates the prognostic role of peripheral blood cells in mRCC patients treated with nivolumab. Methods:The primary endpoint of the study was median overall survival (mOS) according to baseline neutrophil to lymphocyte ratio (NLR), but here preliminary analyses on baseline LMR and SII (secondary endpoints) are reported. LMR was defined as the ratio of lymphocyte to monocyte (cutoff = 3) and SII as platelet x neutrophil/lymphocyte (cutoff = 1375). Results: From May 2016 to January 2019 189 patients started nivolumab as 2nd (62%), 3rd (25%) and > 3rd (13%) line. Median age was 69 years, 67% were male and 87% had clear cell histology. Baseline IMDC group was favorable in 26%, intermediate in 63% and poor in 11%. Lymph-nodes, visceral and bone metastases were present in 55%, 92% and 37%. mOS and progression-free survival (PFS) were 30.5 months and 9.5 months. Overall response rate (ORR) and disease control rate (DCR) were 28% and 57%. LMR was available in 150 patients: LMR ≥ 3 (44%) correlated with statistically significant longer OS [NR vs 26.8 months, HR 0.50 (0.29-0.88); p = 0.016] but not PFS (10.3 vs 9.9 months, HR 0.87 (0.58-1.31); p = 0.5) with similar ORR (34% vs 33%) and DCR (60% vs 63%) compared to LMR < 3. SII was available in 162 patients. SII < 1375 (82%) correlated with statistically significant longer PFS [11.5 vs 3.4 months; HR 2.16 (1.36-3.43), p = 0.001] and OS [NR vs 9.5 months; HR 3.87 (2.21-6.78), p < 0.001] with higher ORR (35% vs 20%) and DCR (65% vs 40%) compared to SII ≥ 1375. Univariate and multivariate analyses adjusted for IMDC group, line of therapy and metastatic sites, confirmed the statistically significant correlation between SII with PFS and OS, but not for LMR. Conclusions: Preliminary analyses of our study showed a prognostic role of baseline SII, while it is uncertain for LMR in mRCC patients treated with nivolumab.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Other
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 751)
Abstract #
751
Poster Bd #
K7
Abstract Disclosures
Similar Abstracts
Abstract
2020 ASCO Virtual Scientific Program
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study.
First Author: Sara Elena Rebuzzi
Abstract
2020 Genitourinary Cancers Symposium
Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.
First Author: Sara Elena Rebuzzi
Abstract
2023 ASCO Annual Meeting
Systemic inflammation markers ratio in heavily pretreated NSCLC patients treated with nivolumab.
First Author: Lela Bitar
Abstract
2022 ASCO Annual Meeting
The prognostic value of peripheral blood inflammatory indices early variation in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (Δ-Meet-URO analysis).
First Author: Sara Elena Rebuzzi